Literature DB >> 26306593

Intermittent inotrope therapy: evidence or belief?

Stephan Ensminger1, Uwe Schulz2, P Christian Schulze3, Friedrich-Wilhelm Mohr4, Jan Gummert2.   

Abstract

Mesh:

Substances:

Year:  2015        PMID: 26306593     DOI: 10.1007/s00392-015-0903-7

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


× No keyword cloud information.
  11 in total

1.  The International Conference on Harmonization Good Clinical Practice guideline.

Authors:  J R Dixon
Journal:  Qual Assur       Date:  1998 Apr-Jun

Review 2.  Inotropic therapy for heart failure: an evidence-based approach.

Authors:  G M Felker; C M O'Connor
Journal:  Am Heart J       Date:  2001-09       Impact factor: 4.749

3.  Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure.

Authors:  Uri Elkayam; Gudaye Tasissa; Cynthia Binanay; Lynne W Stevenson; Mihai Gheorghiade; J Wayne Warnica; James B Young; Barry K Rayburn; Joseph G Rogers; Teresa DeMarco; Carl V Leier
Journal:  Am Heart J       Date:  2007-01       Impact factor: 4.749

Review 4.  Intermittent positive inotrope infusion in the management of end-stage, low-output heart failure.

Authors:  B S Levine
Journal:  J Cardiovasc Nurs       Date:  2000-07       Impact factor: 2.083

5.  Effects of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failure.

Authors:  J T Parissis; S Adamopoulos; D Farmakis; G Filippatos; I Paraskevaidis; F Panou; E Iliodromitis; D Th Kremastinos
Journal:  Heart       Date:  2006-12       Impact factor: 5.994

6.  Comparison of dobutamine versus milrinone therapy in hospitalized patients awaiting cardiac transplantation: a prospective, randomized trial.

Authors:  Juan M Aranda; Richard S Schofield; Daniel F Pauly; Timothy S Cleeton; Tracy C Walker; V Steven Monroe; Dana Leach; Larry M Lopez; James A Hill
Journal:  Am Heart J       Date:  2003-02       Impact factor: 4.749

7.  The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysis.

Authors:  Simon Thackray; Joanne Easthaugh; Nick Freemantle; John G F Cleland
Journal:  Eur J Heart Fail       Date:  2002-08       Impact factor: 15.534

8.  Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial.

Authors:  Alexandre Mebazaa; Markku S Nieminen; Milton Packer; Alain Cohen-Solal; Franz X Kleber; Stuart J Pocock; Roopal Thakkar; Robert J Padley; Pentti Põder; Matti Kivikko
Journal:  JAMA       Date:  2007-05-02       Impact factor: 56.272

Review 9.  Clinical pharmacology of levosimendan.

Authors:  Saila Antila; Stig Sundberg; Lasse A Lehtonen
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 10.  Pharmacokinetics and pharmacodynamics of intravenous inotropic agents.

Authors:  Lasse A Lehtonen; Saila Antila; Pertti J Pentikäinen
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.